Atherosclerotic cardiovascular disease, commonly abbreviated ASCVD, is the umbrella term for heart attacks, strokes, and peripheral artery disease caused by the gradual buildup of fatty, inflammatory deposits called plaques inside artery walls. It remains the leading cause of death worldwide, yet its biology is far more dynamic than the old image of pipes slowly clogging with grease. The process starts decades before any symptom appears, involves the immune system as much as cholesterol, and can be shaped by factors most people have never heard of, from mutations in blood-cell genes to metabolites produced by gut bacteria.
How a Plaque Actually Begins
The story starts with lipoproteins, the protein-wrapped particles that ferry cholesterol and fats through the bloodstream. When certain cholesterol-carrying particles slip beneath the inner lining of an artery, they can get physically trapped in the vessel wall. This trapping, called subendothelial retention, is considered the key initiating event in atherosclerosis.1PubMed. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications The retained particles interact with structural molecules in the artery wall and become chemically modified, most famously through oxidation. Oxidized LDL particles are especially prone to staying put and triggering trouble.2PubMed. SPECT/CT imaging for tracking subendothelial retention of electronegative low-density lipoprotein in vivo
Once those modified particles are stuck, the immune system notices. White blood cells called monocytes migrate into the artery wall and transform into macrophages, whose job is to engulf and digest cellular debris. These macrophages gobble up oxidized LDL, but they are poorly equipped to handle the cholesterol overload that follows.3PubMed Central. Oxidized LDL phagocytosis during foam cell formation in atherosclerotic plaques relies on a PLD2-CD36 functional interdependence Cholesterol piles up inside them, and they swell into what pathologists call foam cells because of the bubbly, lipid-stuffed look under a microscope. The uptake of oxidized LDL, the internal packaging of cholesterol, and the failure of normal cholesterol-export pathways all contribute to foam cell accumulation.4PubMed Central. Modification macrophage to foam cells in atherosclerosis disease: some factors stimulate or inhibit this process The process feeds on itself: foam cells release inflammatory signals that recruit still more immune cells, widening the deposit and setting the stage for a mature plaque.
Why Some Plaques Stay Quiet and Others Cause Heart Attacks
Not all plaques are equally dangerous. Many people walk around for decades with stable plaques that narrow an artery modestly without ever causing an event. The plaques that trigger heart attacks and strokes tend to share a specific anatomy: a large pool of dead cells and lipid debris (often called a necrotic core) capped by a thin layer of fibrous tissue. Researchers call this structure a thin-cap fibroatheroma, and it is widely regarded as the major precursor to acute coronary events.5PubMed. The thin-cap fibroatheroma: a type of vulnerable plaque: the major precursor lesion to acute coronary syndromes When that thin cap tears open, blood contacts the thrombogenic material inside, a clot forms rapidly, and the artery can block in minutes.
What thins the cap? Part of the answer is mechanical. Blood flow creates shear forces along the artery wall, and where those shear forces interact with regions of tissue stiffening inside the plaque, the combination can drive local inflammation and weaken the cap from within.6PubMed. Thin-cap fibroatheroma rupture is associated with a fine interplay of shear and wall stress Cell death within the cap also plays a role, eroding the structural tissue that holds it together.7PubMed. The thin-cap fibroatheroma: a type of vulnerable plaque: the major precursor lesion to acute coronary syndromes Meanwhile, macrophage-derived inflammatory debris can further destabilize the plaque by promoting death of the smooth muscle cells that would normally reinforce the cap.8PubMed. Macrophage extracellular traps accelerate atherosclerosis progression via Rap1 pathway-mediated necroptosis and phenotypic switching in vascular smooth muscle cells
Where Plaques Tend to Form and Why
Atherosclerosis does not develop uniformly throughout the vascular system. Plaques tend to form at bends, branch points, and the inner curvature of arteries where blood flow is sluggish or swirling rather than smooth and brisk. These spots experience low wall shear stress, and research consistently shows that low shear stress promotes the earliest steps of plaque formation while high, laminar shear stress protects against it.9PubMed Central. Wall shear stress and its role in atherosclerosis That is why the coronary arteries, carotid bifurcation, and the arteries feeding the legs are the most common trouble spots. Once a plaque starts growing, it reshapes the local blood flow further, creating new zones of disturbed shear that can make the plaque grow unevenly and change the likelihood of rupture at different points along its surface.
Inflammation as a Driver, Not Just a Bystander
For most of the twentieth century, atherosclerosis was framed almost entirely as a cholesterol-storage problem. That picture has shifted dramatically. Chronic, low-grade inflammation is now recognized as essential to every stage of the disease, from the initial retention of lipoproteins to foam cell formation to the weakening of fibrous caps. Oxidized LDL does not just passively accumulate; it reprograms monocytes, boosting the production of inflammatory cytokines and upregulating the scavenger receptors that pull in still more oxidized LDL.10PubMed. Oxidized low-density lipoprotein induces long-term proinflammatory cytokine production and foam cell formation via epigenetic reprogramming of monocytes That reprogramming is epigenetic, meaning the inflammatory boost persists long after the initial trigger.
The clinical proof that inflammation matters independently came from large trials testing anti-inflammatory drugs in patients who already had well-controlled cholesterol. The CANTOS trial, which targeted a specific inflammatory signaling molecule called interleukin-1β, demonstrated that reducing inflammation could lower the rate of cardiovascular events even without changing LDL levels. This line of research has opened the door to what cardiologists now call “residual inflammatory risk,” the leftover danger that persists after cholesterol is brought under control.
Risk Factors You May Not Have Heard Of
High LDL cholesterol, high blood pressure, smoking, diabetes, and obesity are the traditional ASCVD risk factors, and they deserve their prominence. But several lesser-known contributors are gaining attention.
Lipoprotein(a)
Lipoprotein(a), usually written Lp(a), is a genetically determined variant of LDL that carries an extra protein called apolipoprotein(a). High Lp(a) is an independent, causal risk factor for ASCVD through mechanisms tied to increased plaque formation, inflammation, and clot promotion.11PubMed Central. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association Roughly 1.4 billion people worldwide have elevated levels.12PubMed Central. Lipoprotein(a): An important piece of the ASCVD risk factor puzzle across diverse populations Unlike regular LDL, Lp(a) levels are overwhelmingly set by your genes and barely budge with diet or exercise. Standard statins do not lower it. Dedicated Lp(a)-lowering drugs are in late-stage clinical trials, but for now the main reason to know your level is to understand your overall risk picture more accurately, especially if heart disease runs in your family despite seemingly normal cholesterol numbers.
Remnant Cholesterol
Triglyceride-rich lipoproteins leave behind smaller, cholesterol-laden particles after they deliver fat to tissues. These remnants can penetrate the artery wall much like LDL, and evidence from genetic studies, lab models, and large population analyses consistently supports their role in predicting ASCVD events.13PubMed Central. Triglyceride-Rich Lipoproteins and Remnant Cholesterol in Cardiovascular Disease This helps explain why some people with apparently acceptable LDL levels still develop atherosclerosis: a substantial share of the atherogenic cholesterol entering their artery walls may be arriving on remnant particles rather than on classic LDL.
Clonal Hematopoiesis
As you age, stem cells in your bone marrow occasionally acquire mutations. Sometimes one mutant stem cell outcompetes its neighbors, producing a growing clone of blood cells that all carry the same mutation. This phenomenon, called clonal hematopoiesis of indeterminate potential (CHIP), becomes increasingly common after middle age and has emerged as a potent risk factor for atherosclerosis.14PubMed Central. Clonal hematopoiesis and atherosclerosis In two large prospective studies, carriers of CHIP mutations had roughly twice the risk of coronary heart disease compared with noncarriers, and in cohorts focused on early-onset heart attacks, the risk was about four times higher.15PubMed Central. Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease The connection appears to run through inflammation: mutations in one of the most commonly affected genes, TET2, cause immune cells to ramp up production of inflammatory signaling molecules, which accelerates plaque growth.16Nature Reviews Cardiology. Clonal haematopoiesis: connecting ageing and inflammation in cardiovascular disease CHIP is not yet part of routine clinical screening, but it helps explain why age itself is such a powerful risk factor for ASCVD, and it may eventually become a target for precision treatments.
Air Pollution
Fine particulate matter, the tiny airborne particles labeled PM2.5, accelerates atherosclerosis through pro-oxidant and pro-inflammatory effects that involve multiple organs and cell types.17PubMed. Fine particulate matter air pollution and atherosclerosis: Mechanistic insights People living in heavily polluted areas carry a measurably higher burden of vascular disease, and the effect adds on top of classical risk factors. You can control your cholesterol and blood pressure, but you cannot always control the air you breathe, which is part of why public-health approaches to ASCVD increasingly emphasize environmental policy alongside individual behavior change.
Gut Bacteria and a Molecule Called TMAO
Your gut microbiome converts certain nutrients found in red meat, eggs, and full-fat dairy, specifically choline, L-carnitine, and lecithin, into a compound called trimethylamine. Your liver then oxidizes it into trimethylamine N-oxide (TMAO).18PubMed Central. Trimethylamine-N-oxide (TMAO) and risk of incident cardiovascular events in the multi ethnic study of Atherosclerosis Higher blood TMAO levels promote atherosclerosis in animal models and are associated with platelet hyperreactivity, endothelial dysfunction, and increased clot formation in humans.19PubMed Central. Gut microbiota in atherosclerosis: focus on trimethylamine N-oxide TMAO has also been linked to the risk of stroke through these same atherogenic and thrombotic pathways.20PubMed Central. Gut Microbiota and Ischemic Stroke: The Role of Trimethylamine N-Oxide
This does not mean everyone who eats a steak is headed for a heart attack. The amount of TMAO produced depends heavily on the specific bacterial species living in your gut, which in turn are shaped by your long-term dietary pattern and other factors. People who eat mostly plant-based diets tend to have gut communities that produce less TMAO even when they occasionally consume animal-derived foods. Researchers are exploring whether targeting TMAO production, either through dietary shifts or drugs that block the microbial enzymes involved, could become a useful add-on strategy for ASCVD prevention.
How Doctors Estimate Your Risk
Because ASCVD develops silently for decades, clinicians rely on risk calculators to decide who needs preventive treatment. In the United States, the Pooled Cohort Equations (PCEs) have been the standard tool for estimating 10-year risk since 2013, using age, sex, race, blood pressure, cholesterol levels, diabetes status, and smoking history. More recently, the American Heart Association introduced the PREVENT equations, which incorporate kidney function and metabolic markers and drop race as an input variable. In a large validation study of over half a million adults, both the PREVENT equations and the PCEs showed similar ability to discriminate who would and would not develop an event, but the PCEs consistently overestimated actual 10-year risk, while the PREVENT equations were better calibrated to real-world event rates.21PubMed Central. Use of coronary artery calcium score and coronary CT angiography to guide cardiovascular prevention and treatment
When the calculator puts someone in an intermediate-risk zone and the decision about whether to start medication is unclear, a coronary artery calcium (CAC) score obtained from a low-dose CT scan can help tip the balance. A score of zero is strongly reassuring. A high score, reflecting years of calcified plaque deposits, can motivate both clinician and patient to start statin therapy even if traditional numbers seem borderline. Newer imaging with coronary CT angiography goes further, measuring not just calcium but overall plaque volume and composition, and there is growing interest in using it to track how plaques respond to treatment over time.22PubMed Central. Use of coronary artery calcium score and coronary CT angiography to guide cardiovascular prevention and treatment
Medications That Slow or Reverse the Process
Statins remain the cornerstone of ASCVD prevention and treatment. They work primarily by blocking the liver enzyme responsible for cholesterol production, which forces liver cells to pull more LDL out of the bloodstream. Clinical trials across a wide range of patients have shown that statins reduce major coronary events by roughly 30% in relative terms, with the greatest absolute benefit going to people at highest baseline risk.23PubMed. Current perspectives on statins Beyond LDL lowering, statins appear to improve the stability of plaques, reduce inflammation within the artery wall, and improve the function of the endothelium, the inner lining cells that keep arteries healthy.24PubMed Central. Understanding the molecular mechanisms of statin pleiotropic effects These so-called pleiotropic effects remain a topic of active debate, but they may partly explain why statins perform better in clinical trials than you would predict from their LDL reduction alone.25PubMed Central. Statins: mechanism of action and effects
When statins alone are not enough, several add-on therapies are available. Ezetimibe blocks cholesterol absorption in the intestine by interfering with a specific transport protein, preventing cholesterol from entering intestinal cells and thereby lowering the amount that reaches the bloodstream.26PubMed. The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1 In animal models, blocking this pathway nearly eliminated atherosclerosis development.27PubMed Central. NPC1L1 and Cholesterol Transport PCSK9 inhibitors, given as injections every few weeks, produce large additional drops in LDL and are now widely used in patients at very high risk who cannot reach their targets with pills alone. For patients with type 2 diabetes, newer classes of glucose-lowering drugs, specifically SGLT2 inhibitors and GLP-1 receptor agonists, have shown cardiovascular and kidney benefits that appear to go beyond blood sugar control, likely through effects on oxidative stress, inflammation, and metabolism.
How ASCVD Differs Between Women and Men
Women develop symptomatic ASCVD roughly a decade later than men on average, partly because of the protective effects of estrogen on blood vessel function before menopause. But the disease does not simply arrive later in an identical form. Imaging studies of people undergoing treatment for acute coronary events have found that women tend to have plaques with smaller lipid pools, less cholesterol crystallization, and less calcification, all signs associated with greater stability.28American Physiological Society. Atherosclerosis as the Damocles’ sword of human evolution: insights from nonhuman ape-like primates, ancient human remains, and isolated modern human populations Women’s plaques are, however, more likely to undergo plaque erosion rather than the classic cap rupture that predominates in men. Erosion exposes a different part of the vessel wall to the bloodstream, still triggering a clot but through a somewhat different mechanism. This distinction matters because diagnostic tests and risk calculators were historically built around male-pattern disease, and some researchers argue they still underperform in women.
An Evolutionary Perspective on Why We Are Vulnerable
Atherosclerosis is not simply a disease of modern excess. Evidence of arterial plaques has been found in ancient Egyptian mummies and in pre-industrial populations, suggesting a deep evolutionary susceptibility. One influential hypothesis holds that after the human lineage diverged from other great apes, mutations in immune-regulatory genes produced a more aggressive innate immune system. That hyperactive immunity was advantageous for fighting infections in a world without antibiotics, but it came with a trade-off: the same inflammatory machinery that protects against pathogens also drives plaque formation inside artery walls.29American Physiological Society. Atherosclerosis as the Damocles’ sword of human evolution: insights from nonhuman ape-like primates, ancient human remains, and isolated modern human populations Under this framework, the traditional risk factors we talk about today, metabolic syndrome, psychological stress, sedentary living, may function less as root causes and more as accelerants of an inflammatory process that was always part of the human package. Great apes living in the wild, by contrast, rarely develop significant atherosclerosis despite sharing most of our genome, a gap that appears to trace partly to differences in immune gene expression rather than diet or exercise alone.
This evolutionary lens does not change your doctor’s advice to lower your LDL and manage your blood pressure. But it does reframe ASCVD as something more fundamental than a lifestyle disease. The inflammatory wiring that makes us vulnerable is the same wiring that helped our ancestors survive infections long enough to reproduce. Modern medicine is, in a sense, trying to decouple two things that evolution bundled together: robust immunity and chronic arterial inflammation.